Previously, we demonstrated the preclinical effectiveness of targeting CD38 in mature T-cell neoplasms and we wanted to extend this therapeutic approach to the context of CTCL [3]. This evidence concerns the gene CD38 and T-cell and NK-cell neoplasm.